Self-Amplifying mRNA Vaccine Platform

CSL, Australia's largest biotech company, has developed self-amplifying mRNA (sa-mRNA) vaccine technology through its partnership with Arcturus Therapeutics. Unlike conventional mRNA vaccines (Pfizer, Moderna) that deliver a fixed dose of instructions, sa-mRNA includes a replication mechanism that amplifies the mRNA payload inside cells, producing more antigen protein from a much smaller initial dose. The Kostaive COVID-19 vaccine, using this platform, received EMA approval and is now being extended to seasonal influenza and other infectious diseases.

Self-amplification addresses key limitations of first-generation mRNA vaccines: the need for large doses (causing more reactogenicity), cold chain requirements, and relatively short duration of immunity. By achieving equivalent immune responses at 1/10th the mRNA dose, sa-mRNA vaccines are cheaper to manufacture, easier to store, and potentially suitable for single-dose regimens. CSL's 58 clinical trials across its pipeline (FY2025) demonstrate the platform's versatility.

Australia's position in mRNA manufacturing was catalyzed by the pandemic, when the country's inability to domestically produce mRNA vaccines became a national security concern. CSL's Melbourne-based research, combined with the government's investment in sovereign vaccine manufacturing capability, positions Australia as one of the few nations with end-to-end mRNA vaccine development and production capacity — a critical component of pandemic preparedness and health sovereignty.